Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study

Adugnaw Zeleke Alem, Ejigu Gebeye Zeleke, Temesgen Yihunie Akalu Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Science, University of Gondar, Gondar, EthiopiaCorrespondence: Adugnaw Zeleke Alem Email aduzeleke2201@gmail.comBackground: Early...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zeleke Alem A, Gebeye Zeleke E, Akalu TY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	adjuvant chemotherapy breast cancer survival analysis gondar Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/19f08aa655dc400e86dfdbf03757415f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19f08aa655dc400e86dfdbf03757415f
record_format	dspace
spelling	oai:doaj.org-article:19f08aa655dc400e86dfdbf03757415f2021-12-02T15:35:27ZTime to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study1179-1314https://doaj.org/article/19f08aa655dc400e86dfdbf03757415f2020-09-01T00:00:00Zhttps://www.dovepress.com/time-to-adjuvant-chemotherapy-and-its-predictors-among-women-with-brea-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Adugnaw Zeleke Alem, Ejigu Gebeye Zeleke, Temesgen Yihunie Akalu Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Science, University of Gondar, Gondar, EthiopiaCorrespondence: Adugnaw Zeleke Alem Email aduzeleke2201@gmail.comBackground: Early adjuvant chemotherapy improves the outcomes of breast cancer patients by increasing the benefit provided by the cytotoxic systemic therapies. Despite these, the recommended time to adjuvant chemotherapy and its predictors is very limited. Therefore, this study was determining the time to adjuvant chemotherapy and its predictors among women with breast cancer at the University of Gondar Comprehensive Specialized Hospital.Methods: An institution-based retrospective follow-up study was conducted at the University of Gondar Compressive Specialized Hospital from January 2015 to February 2019 among all women with breast cancer. Stata version 14 was used for data analysis. A stratified Cox regression model was fitted to identify the potential predictors. The adjusted hazard ratio (AHR) with a 95% confidence interval (CI) was reported to show the strength of the association. Cox–Snell residual test was used to check the goodness of fit.Results: In this study, the median time to adjuvant chemotherapy was 67 days with an interquartile range of 34– 102 days. More than three-fourth (79.9%) of patients received chemotherapy after 30 days. Of the total, 96.6% of patients with co-morbidity received adjuvant chemotherapy after 30 days. Regarding surgical complications, 97.0% of the patients with a surgical complications were received adjuvant chemotherapy after 30 days. Older patients (AHR= 0.34, 95% CI: 0.16,0.71), presence of co-morbidity (AHR= 0.43, 95% CI: 0.29, 0.62), positive surgical margin (AHR= 0.40, 95% CI: 0.25, 0.64), and presence of surgical complication (AHR= 0.55, 95% CI: 0.34, 0.88) were significantly associated with delayed time to adjuvant chemotherapy.Conclusion: In this study, time to adjuvant chemotherapy among women was longer. Age, co-morbidity, surgical complications, and margin status were significant predictors of time to adjuvant chemotherapy. Close follow-up is important for women with surgical complications, co-morbidities, elder patients, and patients with a positive margin.Keywords: adjuvant chemotherapy, breast cancer, survival analysis, GondarZeleke Alem AGebeye Zeleke EAkalu TYDove Medical Pressarticleadjuvant chemotherapybreast cancersurvival analysisgondarNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 12, Pp 97-108 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	adjuvant chemotherapy breast cancer survival analysis gondar Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	adjuvant chemotherapy breast cancer survival analysis gondar Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zeleke Alem A Gebeye Zeleke E Akalu TY Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
description	Adugnaw Zeleke Alem, Ejigu Gebeye Zeleke, Temesgen Yihunie Akalu Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Science, University of Gondar, Gondar, EthiopiaCorrespondence: Adugnaw Zeleke Alem Email aduzeleke2201@gmail.comBackground: Early adjuvant chemotherapy improves the outcomes of breast cancer patients by increasing the benefit provided by the cytotoxic systemic therapies. Despite these, the recommended time to adjuvant chemotherapy and its predictors is very limited. Therefore, this study was determining the time to adjuvant chemotherapy and its predictors among women with breast cancer at the University of Gondar Comprehensive Specialized Hospital.Methods: An institution-based retrospective follow-up study was conducted at the University of Gondar Compressive Specialized Hospital from January 2015 to February 2019 among all women with breast cancer. Stata version 14 was used for data analysis. A stratified Cox regression model was fitted to identify the potential predictors. The adjusted hazard ratio (AHR) with a 95% confidence interval (CI) was reported to show the strength of the association. Cox–Snell residual test was used to check the goodness of fit.Results: In this study, the median time to adjuvant chemotherapy was 67 days with an interquartile range of 34– 102 days. More than three-fourth (79.9%) of patients received chemotherapy after 30 days. Of the total, 96.6% of patients with co-morbidity received adjuvant chemotherapy after 30 days. Regarding surgical complications, 97.0% of the patients with a surgical complications were received adjuvant chemotherapy after 30 days. Older patients (AHR= 0.34, 95% CI: 0.16,0.71), presence of co-morbidity (AHR= 0.43, 95% CI: 0.29, 0.62), positive surgical margin (AHR= 0.40, 95% CI: 0.25, 0.64), and presence of surgical complication (AHR= 0.55, 95% CI: 0.34, 0.88) were significantly associated with delayed time to adjuvant chemotherapy.Conclusion: In this study, time to adjuvant chemotherapy among women was longer. Age, co-morbidity, surgical complications, and margin status were significant predictors of time to adjuvant chemotherapy. Close follow-up is important for women with surgical complications, co-morbidities, elder patients, and patients with a positive margin.Keywords: adjuvant chemotherapy, breast cancer, survival analysis, Gondar
format	article
author	Zeleke Alem A Gebeye Zeleke E Akalu TY
author_facet	Zeleke Alem A Gebeye Zeleke E Akalu TY
author_sort	Zeleke Alem A
title	Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
title_short	Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
title_full	Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
title_fullStr	Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
title_full_unstemmed	Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
title_sort	time to adjuvant chemotherapy and its predictors among women with breast cancer at the university of gondar compressive specialized hospital: a retrospective follow-up study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/19f08aa655dc400e86dfdbf03757415f
work_keys_str_mv	AT zelekealema timetoadjuvantchemotherapyanditspredictorsamongwomenwithbreastcancerattheuniversityofgondarcompressivespecializedhospitalaretrospectivefollowupstudy AT gebeyezelekee timetoadjuvantchemotherapyanditspredictorsamongwomenwithbreastcancerattheuniversityofgondarcompressivespecializedhospitalaretrospectivefollowupstudy AT akaluty timetoadjuvantchemotherapyanditspredictorsamongwomenwithbreastcancerattheuniversityofgondarcompressivespecializedhospitalaretrospectivefollowupstudy
_version_	1718386519669997568

Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study

Ejemplares similares